Bluesky Facebook Reddit Email

New gut-brain discovery offers hope for treating ALS and dementia

02.09.26 | Case Western Reserve University

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.


CLEVELAND—A significant discovery by Case Western Reserve University researchers could change how doctors treat two of the most devastating neurodegenerative diseases.

The team identified a link between gut bacteria and the deterioration of the brain in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The researchers discovered that certain bacterial sugars cause immune responses that kill cells—and how to prevent it.

FTD mainly affects the brain’s frontal and temporal lobes, causing changes in a person’s personality, behavior and language. ALS primarily targets motor neurons, resulting in gradual muscle weakness and paralysis.

Most causes of ALS and FTD cases are unknown, although researchers have been examining several potential reasons, including genetics, environmental issues, brain injuries and diet.
The study, recently published in Cell Reports , solves a long-standing question about neurodegenerative diseases. The team discovered a molecular connection that explains why some people with specific genetic mutations acquire FTD and ALS and others don’t.

“We found that harmful gut bacteria produce inflammatory forms of glycogen (a type of sugar), and that these bacterial sugars trigger immune responses that damage the brain,” said Aaron Burberry , assistant professor in the Department of Pathology at the Case Western Reserve School of Medicine.

Burberry, the study’s senior investigator, reported that 70% of the 23 ALS/FTD patients examined had dangerous glycogen levels. Of those without the brain diseases, only a third had high levels of glycogen.

The study has immediate implications for patient care by identifying new targets to treat ALS and FTD, while providing biomarkers to identify patients who might benefit from gut-targeted therapies.

This discovery paves the way for testing new treatments that break down harmful sugars in the gut, and it opens doors for developing drugs that work on the connection between the digestive system and the brain—potentially offering new hope for patients suffering from these devasting brain diseases.

Alex Rodriguez-Palacios , assistant professor in the Digestive Health Research Institute at the School of Medicine, said the team used its findings to then reduce the harmful sugars, which “improved brain health and extended lifespan.”

Their discovery is particularly significant for what is known as C90RF72 mutation carriers—the most common genetic cause of ALS and FTD. The research explains why some people with the mutation develop the diseases while others don’t, identifying gut bacteria as a key environmental trigger.

The university’s Department of Pathology and Digestive Health Research Institute are leading neurovegetative disease research through their unique ability to conduct studies using germ-free mouse models—mice raised in completely sterile environments with no bacteria, allowing researchers to study exactly how specific gut bacteria affect brain diseases.

Fabio Cominelli , Distinguished University Professor and director of the Digestive Health Research Institute, oversees this program, which relies on an innovative “cage-in-cage” sterile housing system developed by Rodriguez-Palacios—a technical capability that few institutions worldwide possess and that made this discovery possible.

The design makes possible the large-scale microbiological studies necessary to understand the complex communication between the gut and brain—research that would be impossible with traditional methods that can only accommodate a few mice at a time, and a technical capability that few institutions worldwide possess.

“To understand when and why harmful microbial glycogen is produced, the team will next conduct larger studies surveying gut microbiome communities in ALS/FTD patients before and after disease onset,” Burberry said. “Clinical trials to determine whether glycogen degradation in ALS/FTD patients could slow disease progression are also supported by our findings and could begin in a year.”

###

About Case Western Reserve University

As one of the fastest-growing research universities in the United States, Case Western Reserve University is a force in career-defining education and life-changing research. Across our campus, more than 12,000 students from around the world converge to seek knowledge, find solutions and accelerate their impact. They learn from and collaborate with faculty members renowned for expertise in medicine, engineering, science, law, management, dental medicine, nursing, social work, and the arts. And with our location in Cleveland, Ohio—a hub of cultural, business and healthcare activity—our students gain unparalleled access to academic, research, clinical and entrepreneurial opportunities that prepare them to join our network of more than 125,000 alumni worldwide. Visit case.edu to see why Case Western Reserve University is built for those driven to be a force in the world.

Cell Reports

10.1016/j.celrep.2025.116906

Experimental study

Animals

C9orf72 in myeloid cells prevents an inflammatory response to microbial glycogen

24-Feb-2026

Keywords

Article Information

Contact Information

William Lubinger
Case Western Reserve University
wxl289@case.edu

How to Cite This Article

APA:
Case Western Reserve University. (2026, February 9). New gut-brain discovery offers hope for treating ALS and dementia. Brightsurf News. https://www.brightsurf.com/news/LDEM4NK8/new-gut-brain-discovery-offers-hope-for-treating-als-and-dementia.html
MLA:
"New gut-brain discovery offers hope for treating ALS and dementia." Brightsurf News, Feb. 9 2026, https://www.brightsurf.com/news/LDEM4NK8/new-gut-brain-discovery-offers-hope-for-treating-als-and-dementia.html.